Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y101D plus bevacizumab in advanced hepatocellular carcinoma and other advanced solid tumors
CTR20230372Phase 2Terminated
- Sponsor
- YZY Biopharma
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Y101D, bevacizumab in hepatocellular carcinoma (HCC), Nonhematologic neoplasms, sponsored by YZY Biopharma. Started Mar 2023; status: terminated.
02
Drugs
Y101Dbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20230372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230372.